Your browser doesn't support javascript.
loading
Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China.
Ma, Yan; Zhu, Dong Shan; Chen, Ren Bo; Shi, Nan Nan; Liu, Si Hong; Fan, Yi Pin; Wu, Gui Hui; Yang, Pu Ye; Bai, Jiang Feng; Chen, Hong; Chen, Li Ying; Feng, Qiao; Guo, Tuan Mao; Hou, Yong; Hu, Gui Fen; Hu, Xiao Mei; Hu, Yun Hong; Huang, Jin; Huang, Qiu Hua; Huang, Shao Zhen; Ji, Liang; Jin, Hai Hao; Lei, Xiao; Li, Chun Yan; Li, Min Qing; Li, Qun Tang; Li, Xian Yong; Liu, Hong De; Liu, Jin Ping; Liu, Zhang; Ma, Yu Ting; Mao, Ya; Mo, Liu Fen; Na, Hui; Wang, Jing Wei; Song, Fang Li; Sun, Sheng; Wang, Dong Ting; Wang, Ming Xuan; Wang, Xiao Yan; Wang, Yin Zhen; Wang, Yu Dong; Wu, Wei; Wu, Lan Ping; Xiao, Yan Hua; Xie, Hai Jun; Xu, Hong Ming; Xu, Shou Fang; Xue, Rui Xia; Yang, Chun.
Afiliação
  • Ma Y; Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
  • Zhu DS; Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.
  • Chen RB; Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
  • Shi NN; Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
  • Liu SH; Institute of Information on Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
  • Fan YP; Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
  • Wu GH; Department of Tuberculosis, The Public Health Clinical Center of Chengdu, Chengdu 610066, Sichuan, China.
  • Yang PY; Department of Infectious Disease, Shaanxi Infectious Disease Hospital, Xi'an 610113, Shaanxi, China.
  • Bai JF; Department of Infectious Disease, Yulin Chinese Medicine Hospital, Yulin 719000, Shaanxi, China.
  • Chen H; President's Office, The First Hospital of Qiqihar, Qiqihar 161005, Heilongjiang, China.
  • Chen LY; Department of Traditional Chinese Medicine, Shangluo Central Hospital, Shangluo 726000, Shaanxi, China.
  • Feng Q; Department of Traditional Chinese Medicine, The People's Hospital of Qitaihe, Qitaihe 154603, Heilongjiang, China.
  • Guo TM; Department of Scientific Research, Xianyang Central Hospital, Xianyang 712000, Shaanxi, China.
  • Hou Y; Department of traditional Chinese medicine, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei 230012, Anhui, China.
  • Hu GF; Department of Infectious Disease, Heping Hospital Affiliated to Changzhi Medical College, Changzhi 046000, Shanxi, China.
  • Hu XM; Department of Traditional Chinese Medicine, Langfang Hospital of Chinese Medicine, Langfang 065000, Heibei, China.
  • Hu YH; Department of Traditional Chinese Medicine, Xingtai Hospital of Chinese Medicine, Xingtai 054001, Heibei, China.
  • Huang J; Department of Traditional Chinese Medicine, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 168600, Guangxi, China.
  • Huang QH; Department of Traditional Chinese Medicine, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 168600, Guangxi, China.
  • Huang SZ; Department of Traditional Chinese Medicine, The First People's Hospital of Fangchenggang, Fangchenggang 538001, Guangxi, China.
  • Ji L; Department of Traditional Chinese Medicine, Mianyang Hospital of Traditional Chinese Medicine, Mianyang 621000, Sichuan, China.
  • Jin HH; Department of Traditional Chinese Medicine, Liuzhou People's Hospital, Liuzhou 545006, Gansu, China.
  • Lei X; Department of Traditional Chinese Medicine, Affiliated Hospital of North Sichuan Medical College, Nanyun 637000, Sichuan, China.
  • Li CY; Department of Infectious Disease, Yan'an Second People's Hospital, Yan'an 716000, Shaanxi, China.
  • Li MQ; Department of Traditional Chinese Medicine, Dazhou Central Hospital, Dazhou 635000, Sichuan, China.
  • Li QT; Chongqing Traditional Chinese Medicine Hospital, Chongqing 400011, China.
  • Li XY; The Second People's Hospital of Neijiang, Neijiang 641000, Sichuan, China.
  • Liu H; Shijiazhuang Fifth Hospital, Shijiazhuang 050021, Hebei, China.
  • Liu JP; Department of Infectious Disease, The Fourth People's Hospital of Taiyuan, Taiyuan 030053, Shanxi, China.
  • Liu Z; Department of Traditional Chinese Medicine, The First Hospital of Suihua City, Suihua 152053, Heilongjiang, China.
  • Ma YT; Department of Traditional Chinese Medicine, The Fourth People's Hospital of Nanning, Nanning 530023, Guangxi, China.
  • Mao Y; Department of Infectious Disease, Ankang Hospital of Traditional Chinese Medicine, Ankang 725000, Shaanxi, China.
  • Mo LF; Department of Infectious Disease, Beihai Hospital of Chinese Medicine, Beihai 536000, Guangxi, China.
  • Na H; Department of Infectious Disease, Harbin Infectious Disease Hospital, Harbin 150036, Heilongjiang, China.
  • Wang JW; Department of Infectious Disease, Harbin Infectious Disease Hospital, Harbin 150036, Heilongjiang, China.
  • Song FL; Department of Infectious Disease, The Third People's Hospital of Linfen, Linfen 041000, Shanxi, China.
  • Sun S; Department of Traditional Chinese Medicine, Chengde Hospital of Traditional Chinese Medicine, Chengde 067000, Hehei, China.
  • Wang DT; Department of Infectious Disease, Datong Fourth Hospital, Datong 037008, Shanxi, China.
  • Wang MX; Department of Traditional Chinese Medicine, Suining Central Hospital, Suining 629000, Sichuan, China.
  • Wang XY; Department of Infectious Disease, Jinzhong Infectious Disease Hospital, Jinzhong 030600, Shanxi, China.
  • Wang YZ; Department of Infectious Disease, Jincheng People's Hospital, Jincheng 048026, Shanxi, China.
  • Wang YD; Hengshui Hospital of Chinese Medicine, Hengshui 053000, Heibei, China.
  • Wu W; President's office, Hanzhong Central Hospital, Hanzhong 723000, Hubei, China.
  • Wu LP; Department of Infectious Disease, Shuozhou People's Hospital, Shuozhou 036002, Shanxi, China.
  • Xiao YH; Department of Traditional Chinese Medicine, Mudanjiang Kangan Hospital, Mudanjiang 157011, Heilongjiang, China.
  • Xie HJ; Department of Infectious Disease, Xinzhou People's Hospital, Xinzhou 034000, Shanxi, China.
  • Xu HM; Department of Infectious Disease, Daqing Second Hospital, Daqing 163000, Heilongjiang, China.
  • Xu SF; Department of Traditional Chinese Medicine,Jiamusi Infectious Disease Hospital, Jiamusi 154007, Heilongjiang, China.
  • Xue RX; Department of Infectious Disease, Yuncheng Second Hospital, Yuncheng 044000, Shanxi, China.
  • Yang C; Department of Traditional Chinese Medicine, Hanzhong Hospital for Infectious Diseases, Hanzhong 723000, Hubei, China.
Biomed Environ Sci ; 33(12): 893-905, 2020 Dec 20.
Article em En | MEDLINE | ID: mdl-33472729
OBJECTIVE: Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains unclear. METHODS: A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients' medical records. Multivariable logistic regression models were used to estimate the odds ratio ( OR) and 95% confidence interval (95% CI) of the associations between comorbidities (cardiometabolic or non-cardiometabolic diseases), clinical severity, and treatment outcomes of COVID-19. RESULTS: Overall, 158 (13.6%) patients were diagnosed with severe illness and 32 (2.7%) had unfavorable outcomes. Hypertension (2.87, 1.30-6.32), type 2 diabetes (T2DM) (3.57, 2.32-5.49), cardiovascular disease (CVD) (3.78, 1.81-7.89), fatty liver disease (7.53, 1.96-28.96), hyperlipidemia (2.15, 1.26-3.67), other lung diseases (6.00, 3.01-11.96), and electrolyte imbalance (10.40, 3.00-26.10) were independently linked to increased odds of being severely ill. T2DM (6.07, 2.89-12.75), CVD (8.47, 6.03-11.89), and electrolyte imbalance (19.44, 11.47-32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission (5.46, 3.25-9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes (6.58, 1.46-29.64) within two weeks. CONCLUSION: Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Biomed Environ Sci Assunto da revista: SAUDE AMBIENTAL Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Biomed Environ Sci Assunto da revista: SAUDE AMBIENTAL Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China